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Objectives: Personalized medicine has become standard of care in directing 
treatment with tyrosine kinase inhibitors in locally advanced or metastatic NSCLC 
patients, but various testing methods for identifying EGFR mutations exist. We 
compared the clinical outcomes and budget impact of using the FDA-approved 
cobas® EGFR Mutation Test versus Sanger sequencing for identifying EGFR muta-
tions in locally advanced or metastatic NSCLC patients from a US payer per-
spective. MethOds: A decision-tree model was developed to compare testing 
methodologies and resulting treatment pathways in a hypothetical NSCLC US 
population health plan with 5 million covered lives and a baseline EGFR muta-
tion prevalence of 16.6%. Model inputs included parameters describing mutation 
testing accuracy treatment response (EGFR inhibitor, standard chemo therapy or 
best supportive care). Inputs were based on published literature and Medicare 
fee schedule reimbursement. Outcomes of the model included patients with test 
failures (based on detection limits of testing), average patient survival time and 
budget impact. Results: Patients whose samples were tested with the cobas® 
EGFR Mutation Test were less likely to experience test failures due to unusable tis-
sue samples compared to Sanger sequencing (6 test failures versus 57, respectively). 
Patients using the cobas® EGFR mutations testing received more appropriate care 
compared to Sanger sequencing (90% vs 82%, respectively), resulting in an average 
total survival increase of 0.6 months. Costs associated with diagnostic testing were 
$24,562 less than testing with Sanger sequencing, resulting in similar overall costs 
per member per month ($0.56). cOnclusiOns: Performing EGFR mutation testing 
with the cobas® EGFR Mutation Test has advantages from both patient outcomes 
and payer budget impact perspectives. By correctly identifying more patients for 
proper treatment with less test failures, the cobas® EGFR Mutation Test is a cost-
effective strategy for identification of EGFR mutations in locally advanced or meta-
static NSCLC patients from a US payer perspective.
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Objectives: Approximately 7,000 Canadians have multiple myeloma (MM). Without 
effective treatment, patients can suffer from a constellation of disease-related 
symptoms that significantly reduce quality of life and survival. Management of stem 
cell transplant (SCT) ineligible MM patients is complex and varied. Maintenance 
therapies (MTs) after various induction regimens have been shown to improve 
response rate and progression-free survival. We sought to compare Canadian costs 
between two common approaches to MT, either bortezomib or lenalidomide, in 
MM patients ineligible for SCT. MethOds: The total annual drug cost of the two 
MT options were calculated and compared. Costs were based on 1.3mg/m2 of bort-
ezomib on days 1, 4, 8, 11 every three months, plus 50 mg of prednisone every 
other day, or 10 mg of lenalidomide on days 1 through 21 of each 28-day cycle. 
Administration costs including oncology nursing time and pharmacist workload, 
and pharmacy costs including a 10% markup and dispensing fees were added to the 
acquisition cost of bortezomib and lenalidomide, respectively. Unit and labour costs 
were obtained from public Canadian sources. Additional analyses were conducted 
to consider the impact of several variables including the management of adverse 
events, treatment duration and alternate costing assumptions. Results: The total 
annual costs of treatment per patient were $20,106, and $108,741 for bortezomib 
and lenalidomide, respectively. The incremental differences were robust to changes 
in inputs and assumptions (to be presented in poster). cOnclusiOns: The results 
of this analysis suggest that substantial savings were associated with bortezomib 
MT when compared with lenalidomide MT. As drug costs represent an increasing 
proportion of public spending in Canada, it is important to consider both efficacy 
and cost of treatment. Further studies are required to determine the complete cost-
benefit of available MTs.
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Objectives: In the UK, anastomotic leak rate after colorectal surgeries has been 
reported up to 19%. Yet, clinical and economic consequences of anastomotic leak 
have not been clearly articulated. Our study aims to estimate the clinical/economic 
burden of anastomotic leak following colorectal surgeries in the UK. MethOds: The 
Hospital Episode Statistics database was used to identify English National Health 
Service Trust adult patients undergoing colorectal surgeries between January 2007 
and December 2011. Anastomotic leak was identified by re-intervention/diagnosis 
codes within a 30-day window following colorectal surgery, including re-opera-
tion, re-anastomosis, stent, colostomy, image guided drainage, washout procedure, 
abscess/drainage and diagnosis of generalized (acute) peritonitis. Hospital costs 
were calculated using Healthcare Resource Group and Department of Health refer-
ence index costs. Differences in outcomes between groups were compared using a 
propensity score matching approach, adjusting for age, gender, admission method, 
surgery type, comorbidity and medical stabilization. Results: A total of 131,689 
patients received colorectal surgeries (mean age: 65.2±15.4, male: 50.4%). The rate 
Objectives: Based on evidence from the National Lung Cancer Screening Trial 
(NLST), the U.S. Preventive Services Task Force(USPSTF) recently recommended 
annual low-dose computed tomography(LDCT) screening for patients that are age 
55-80, have a 30 pack-year smoking history, and currently smoke or quit within the 
past 15 years. Under the terms of the Affordable Care Act, participating plans must 
cover this screening procedure. We project the 5-year clinical, resource, and budget 
impact of implementing this policy. MethOds: We developed a forecasting model 
to estimate the 5-year incremental outcomes of implementing LDCT screening in 
accordance with USPSTF recommendations versus no screening. We considered 
commercial (age < 65) and Medicare (age 65+) populations with 165.1 million and 
51.7 million enrollees, respectively (in accordance with national insurance esti-
mates). Age-specific lung cancer detection rates and stage at diagnosis was derived 
from the NLST. Included costs were LDCT screening and follow-up, confirmatory 
bronchoscopy/biopsy, and stage-specific treatment (initial,continuing,terminal 
care). We estimated lung cancers detected, LDCT scans, and the total and per-
member per-month(PMPM) budget impact of covering LDCT screening, assuming 
100% adherence to USPSTF recommendations in the base case. Monetary results 
are reported in 2013 USD and discounted at 3% per year. Results: In commercial 
and Medicare plans, LDCT screening is expected to result in 84,000 and 141,000 
more lung cancers detected (predominantly Stage I),22.4 million and 37.5 million 
more LDCT scans,and increased overall expenditure of $16.4 billion(PMPM= $1.65) 
and $27.4 billion(PMPM= $8.84), respectively. The most influential parameters were 
the proportion of “high risk” patients electing to undergo screening, the rate of 
screening adoption in the community, and the initial treatment cost of early-stage 
lung cancer. cOnclusiOns: Our analysis suggests that coverage of LDCT lung 
cancer screening is expected to increase lung cancer diagnoses,result in a greater 
proportion of early-stage disease diagnoses, and substantially increase health plan 
expenditure, particularly in Medicare.
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Objectives: This study analyzes the cost of adverse events associated with 
metastatic renal cell carcinoma (mRCC) treatments of pazopanib and suni-
tinib. MethOds: A cost analysis was performed based on the published data of 
the COMPARZ study. All adverse events (AEs) were identified based on the AEs 
reported in this study, Cost information related to the the treatment of the most 
frequent adverse events (> 15%) in the study population (n= 1,100 individuals) 
were obtained. These events included in the analysis were hepatotoxicity, anemia, 
nausea, fatigue and diarrhea. The perspective adopted in this analysis was of the 
Unified Health System (SUS) and Brazilian Supplementary Healthcare (SS). For reck-
oning purposes, the Medication Market Regulation Chamber (CMED/ ANVISA) listed 
prices were used. Results: From the perspective of the SUS, the following results 
are reported: nausea (sunitinib = BRL157.30 vs pazopanib = BRL176.49); anemia 
(sunitinib = BRL33.40 vs pazopanib = BRL14.32); fatigue (sunitinib = BRL18.00 vs 
pazopanib = BRL9.36); diarrhea (sunitinib = BRL73.09 vs pazopanib = BRL125.87) and 
hepatotoxicity (sunitinib = BRL416.18 vs pazopanib = BRL407.13). When consider-
ing costs incurred from private pay perspective such as SS, we observed the values 
were: nausea (sunitinib = BRL697.00 vs pazopanib = BRL782.00); anemia (sunitinib 
= BRL188.52 vs pazopanib = BRL80.79); fatigue (sunitinib = BRL163.11 vs pazopanib 
= BRL84.81) diarrhea (sunitinib = BRL248.66 vs pazopanib = BRL428.24) and hepa-
totoxicity (sunitinib = BRL2,080.90 vs pazopanib = BRL2,035.67). Thus, as from total 
estimated AE events cost, the SUS disbursed approximately BRL697.97 when the first 
line therapeutic option was sunitinib and BRL733.16 with pazopanib. In SS, it was 
paid around BRL3,378.18 and BRL3,411.51, respectively. cOnclusiOns: A therapy 
that has less financial impact on the treatment of adverse events is the choice of 
sunitinib for both public (5% decrease) and private (1%) targets.
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Objectives: A substantial proportion of prostate cancer care (PCa) is expected 
to be completed in the outpatient hospital setting, particularly as more hospitals 
systems acquire oncology practices. However, there is very limited information on 
practice-specific costs of care for patients receiving chemotherapeutic treatments 
within this unique setting. This study evaluated the cost of care for chemotherapy 
treatment in the outpatient hospital setting for PCa patients with bone metasta-
ses. MethOds: Patients in the Premier Hospital Database between January 2006 
and December 2010 treated in an outpatient setting for PCa (ICD-9-CM Codes 185 
and 233.4) were selected. Patients were required to be ≥ 40 years of age and have no 
additional cancers and evidence of bone metastases (ICD-9-CM code 198.5 or the 
use of zoledronic acid or pamidronate disodium). Costs of care per visit across cost 
centers were evaluated and described. Results: There were 5,223 outpatient visits 
for men treated for PCa with bone metastases. The mean age of the sample was 71 
years, with 64% being Caucasian. The average visit cost was $4,614. Pharmacy costs 
($4,119) represent 89.2% of total visit costs, followed by professional ($190) and labo-
ratory expenses ($77). Chemotherapy costs represented 47% of total pharmacy costs, 
with the most commonly specified chemotherapies being docetaxel, mitoxantrone, 
and carboplatin. cOnclusiOns: Men treated for PCa with bone metastases treated 
in an outpatient setting averaged $4,614 per visit, with pharmaceutical costs rep-
resenting almost 90% of care.
